38213-69-3
中文名称
双(麦芽醇)氧钒(IV)
英文名称
Bis(maltolato)oxovanadium(IV)
CAS
38213-69-3
分子式
C12H10O7V
分子量
317.15
MOL 文件
38213-69-3.mol
更新日期
2023/03/20 15:41:17
38213-69-3 结构式
基本信息
中文别名
双(麦芽醇)氧钒(IV) 英文别名
BMOVBIS(MALTOLATO)OXOVANADIUM
BIS(MALTOLATO)OXOVANADIUM(IV)
oxovanadium(2+) bis(2-methyl-4-oxo-4H-pyran-3-olate)
(SP-5-31)-Bis[3-(hydroxy-κO)-2-Methyl-4H-pyran-4-onato-κO4]oxovanadiuM
Vanadium,bis[3-(hydroxy-kO)-2-methyl-4H-pyran-4-onato-kO4]oxo-, (SP-5-31)-
所属类别
原料药
双(麦芽醇)氧钒(IV)价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/02/08 | HY-118567 | 双(麦芽醇)氧钒(IV) Bis(maltolato)oxovanadium(IV) | 38213-69-3 | 5 mg | 400元 |
| 2025/02/08 | HY-118567 | 双(麦芽醇)氧钒(IV) Bis(maltolato)oxovanadium(IV) | 38213-69-3 | 10 mM * 1 mLin DMSO | 440元 |
| 2025/02/08 | HY-118567 | 双(麦芽醇)氧钒(IV) Bis(maltolato)oxovanadium(IV) | 38213-69-3 | 10mg | 600元 |
常见问题列表
生物活性
BMOV (Bis maltolato oxovanadium, Bis(maltolato)oxovanadium (IV))是一种有效的口服钒复合物，具有抗糖尿病特性和模仿胰岛素的作用。BMOV被证明可改善糖尿病模型的心脏功能障碍。靶点
IC50: 126 nM (HCPTPA), 109 nM (PTP1B), 26 nM (HPTPβ) and 201 nM (SHP2)
体外研究
Bis(maltolato)oxovanadium(IV) treatment enhances the phosphorylation of the insulin receptor and of the insulin signalling key intermediate Akt. Bis(maltolato)oxovanadium(IV) (BMOV; 50 μM) treatment also resultes in an increased glucose uptake in C2C12 cells.
体内研究
Bis(maltolato)oxovanadium(IV) (BMOV; 0.75-3.0 mmol; intraperitoneal injection; twice weekly; for 6 weeks; C57BL/6J mice) treatment ameliorates the metabolic phenotype. Liver, skeletal muscle, and adipose tissue revealed a significantly reduced PTP activity in all analysed tissues compared to HFD mice.
| Animal Model: | C57BL/6J mice (4-6 weeks) fed with high-fat diet (HFD) |
| Dosage: | 0.75-3.0 mmol |
| Administration: | Intraperitoneal injection; twice weekly; for 6 weeks |
| Result: | Ameliorated the metabolic phenotype, as evidenced by reduced body weight, improved insulin sensitivity and glucose tolerance. |